{"id":"esg401","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed clinical trial data or published mechanism information, the precise molecular target and pharmacological action of ESG401 cannot be reliably determined. Phase 3 status indicates it has progressed through early safety and efficacy testing, but mechanism details remain proprietary or unpublished.","oneSentence":"ESG401 is an investigational drug in phase 3 development by Qilu Pharmaceutical, but its specific mechanism of action is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:30.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06732323","phase":"PHASE3","title":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-04","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":504},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT04892342","phase":"PHASE1, PHASE2","title":"Study of ESG401 in Adults With Solid Tumors","status":"COMPLETED","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","startDate":"2021-09-14","conditions":"Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal","enrollment":156},{"nctId":"NCT06383767","phase":"PHASE3","title":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-07-11","conditions":"Metastatic Breast Cancer","enrollment":378}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ESG401","genericName":"ESG401","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}